CX ilegx Collaboration Day

Thursday 30 April – Grey Learning Centre

Course director: Michael Edmonds, Cliff Shearman, Iris Baumgartner and Thomas Zeller

ilegxwheel_Main

The CX ilegx Collaboration Day course has been designed to update attendees on the latest treatment strategies developed to avoid the increasing number of unnecessary lower limb amputations ‒ flagship principles of the ilegx initiative.

The ilegx initiative is a collaboration of like-minded health professionals, patients and care workers who share the view that too many legs are amputated and many of these are completely unnecessary. The Charing Cross Symposium has held a dedicated ilegx session since 2008.

In 2015, delegates will learn about the King’s College Hospital open access vascular diabetic foot care pathway ‒ an effective approach which incorporates early diabetic foot referral and interdisciplinary work ‒ which is showing promising results saving limbs. They will also hear about revascularisation strategies of the ischaemic foot with the latest data in the field; and will have the opportunity to discuss in more detail, in two roundtables led by experts, the controversy of “Leaving something in” or “Leaving nothing behind” in the superficial femoral artery.

Click here to read a news story on the ilegx Collaboration Day 2015.

jQuery UI Accordion - Default functionality

Thursday 30 April 2015

Diabetic Vascular Disease Symposium
Chairing: Michael Edmonds, London, United Kingdom
08:00-08:05 Introduction to the ilegx day
Michael Edmonds, London, United Kingdom
08:05-08:15 Amputation rates around the world
Edward Jude, Ashton-under-Lyne, United Kingdom
08:15-08:25 Time is tissue
Jonathan Valabhji, Imperial College, London, United Kingdom
08:25-08:35 Designing a diabetic foot service
Cliff Shearman, Southampton, United Kingdom
08:35-08:45 Novel wound therapies
Toby Richards, London, United Kingdom
08:45-08:55 EndoVAC hybrid treatment of vascular infection – long-term results
Anders Wanhainen, Uppsala, Sweden
08:55-09:05 Discussion The King’s College Hospital open access vascular diabetic foot care pathway
Chairing: Michael Edmonds, London, United Kingdom
09:05-09:15 The importance of open access and rapid assessment
Michael Edmonds, London, United Kingdom
09:15-09:25 Advances in distal open vascular surgery in the diabetic foot pathway
Hisham Rashid, London, United Kingdom
09:25-09:35 Advances in distal endovascular surgery in the diabetic foot pathway
Dean Huang, London, United Kingdom
09:35-09:45 New wound care techniques for tissue loss in the diabetic ischaemic foot
Jennifer Tremlett, London, United Kingdom
09:45-10:00 Discussion COFFEERevascularisation of the ischaemic foot
Chairing: Cliff Shearman, Southampton, United Kingdom
10:30-10:37 The timing of revascularisation
Robert Hinchliffe, London, United Kingdom
10:37-10:44 Choice of revascularisation method
Keith Jones, London, United Kingdom
10:44-10:50 Discussion 10:50-10:57 Endovascular first
Trevor Cleveland, Sheffield, United Kingdom
10:57-11:04 Surgery has its place
Patrick Chong, Frimley, United Kingdom
11:04-11:10 Discussion 11:10-11:17 Follow-up of endo or open revascularisation – duplex use
Alun Davies, Imperial College, London, United Kingdom
11:17-11:24 CRITISCH registry
Theodosios Bisdas, Münster, Germany
11:24-11:31 Evaluation of a robotic system for femoropopliteal interventions
Marianne Brodmann, Graz, Austria
11:31-11:37 Discussion Surgical update and transatlantic surgical trials 11:37-11:44 Arm vein use for lower limb salvage
Mahmoud Malas, Baltimore, United States
11:44-11:51 WiFi classification of the diabetic ischaemic foot
Joseph Mills, Tucson, United States
11:51-11:57 Discussion 11:57-12:07 BASIL 2 and 3 trials
Andrew Bradbury, Birmingham, United Kingdom
12:07-12:17 BEST-CLI trial
Matthew Menard, Boston, MA, United States
12:17-12:23 Discussion LUNCH "Leaving nothing behind" and "Leaving something in"
Chairing: Roger Greenhalgh, London, United Kingdom
"Leaving nothing behind" 13:30-13:36 Mechanisms of action of the Lutonix drug-eluting balloon
Elena Ladich, Gaithersburg, United States
13:36-13:41 Discussion 13:41-13:47 Take everything detachable out of the vessel and treat the target lesion and not the occluded vessel segment
Michael Lichtenberg, Arnsberg, Germany
13:47-13:52 Discussion 13:52-13:58 Atherectomy and the use of DEB
Koen Keirse, Tienen, Belgium
13:58-14:03 Discussion 14:03-14:09 Lessons from the lithoplasty registry
Michael Jaff, Boston, United States
14:09-14:14 Discussion 14:14-14:20 Bioresorbable state of art for SFA
Speaker: Michael Dake, Stanford, United States
14:20-14:25 Discussion 14:25-14:31 Stent: an old memory in the DCB era
Fabrizio Fanelli, Rome, Italy
14:31-14:36 Discussion 14:36-14:42 Lesions suitable for drug-coated balloons
Konstantinos Katsanos, London, United Kingdom
14:42-14:47 Discussion 14:47-14:53 Why bailout stent rates vary so much after DCB and dissection management
Peter Schneider, Honolulu, United States
14:53-14:58 Discussion 14:58-15:04 Differences in types of DEB and consequent outcome variations
Michael Jaff, Boston, United States
15:04-15:09 Discussion 15:09-15:30 Panel discussion on "Leaving nothing behind" TEA 16:00-16:05 DEB vs. BMS vs. Supera
Sabine Steiner, Leipzig, Germany
16:05-16:10 The reality of leaving nothing behind
Peter Gaines, Sheffield, United Kingdom
16:10-16:20 Discussion "Leaving something in" 16:20-16:25 When the pathophysiology of SFA disease requires a permanent implant in order to counteract negative remodelling
Jos van den Berg, Lugano, Switzerland
16:25-16:30 Discussion 16:30-16:35 SFA lesions that need a stent
Jim Reekers, Amsterdam, Netherlands
16:35-16:40 Discussion 16:40-16:45 SUPERA use even with calcification
Peter Goverde, Antwerp, Belgium
16:45-16:50 Discussion 16:50-16:55 Mid-term and late sustained effectiveness: examining the relative durability of endovascular therapies
Michael Dake, Stanford, United States
16:55-17:00 Discussion 17:00-17:05 Lesions suitable for Smart Flex
Eric Ducasse, Bordeaux, France
17:05-17:10 Discussion 17:10-17:15 The BioMimics stent
Speaker: Stephen Williams, Baltimore, United States
17:15-17:20 Discussion 17:20-17:25 Viabahn for long lesions
Daniele Savio, Turin, Italy
17:25-17:30 Discussion 17:30-17:35 Viabhan for restenosis
Jorge Fernandez Noya, Madrid, Spain
17:35-17:40 Discussion 17:40-18:00 Panel discussion on "Leaving something in"